Clinical efficacy of thalidomide combined VAD regimen in the treatmen of 22 cases multiple myeloma
Wang Ya
Abstract
Wang Ya
Abstract
Objective To observe the clinical curative effect of thalidomide combined VAD regimen on treating newly diagnosed multiple myeloma(MM)patiens.Methods Of 22 patients with newly diagnosed MM treated with thalidomide combined VAD regimen.Every 21 days a course of treatment,An intermittent 4 weeks after treatment,Observation of efficacy and toxicity of drugs.Results After treatment for 3 treatments,Among the 22 patients 6 achieved partial remission(27.2%),12 improved(54.5%)and the total effective rate 81.8%.Drug toxicity were bone marrow suppression,fingertip numbness and constipation etc.Conclusion Treating newly diagnosed multiple myeloma(MM)patiens with thalidomide combined VAD regimen can obtain a better efficacy,which is worth to practice in clinics.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To observe the clinical curative effect of thalidomide combined VAD regimen on treating newly diagnosed multiple myeloma(MM)patiens.Methods Of 22 patients with newly diagnosed MM treated with thalidomide combined VAD regimen.Every 21 days a course of treatment,An intermittent 4 weeks after treatment,Observation of efficacy and toxicity of drugs.Results After treatment for 3 treatments,Among the 22 patients 6 achieved partial remission(27.2%),12 improved(54.5%)and the total effective rate 81.8%.Drug toxicity were bone marrow suppression,fingertip numbness and constipation etc.Conclusion Treating newly diagnosed multiple myeloma(MM)patiens with thalidomide combined VAD regimen can obtain a better efficacy,which is worth to practice in clinics.
Key concepts: Medicine, Thalidomide, Regimen, Multiple myeloma, Constipation, Surgery, Internal medicine, Clinical efficacy